FY2025 EPS Estimates for MannKind Cut by Leerink Partnrs

MannKind Co. (NASDAQ:MNKD) – Leerink Partnrs decreased their FY2025 earnings estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will earn $0.16 per share for the year, down from their prior forecast of $0.18. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

Other research analysts have also recently issued research reports about the company. Wells Fargo & Company initiated coverage on MannKind in a research note on Friday. They set an “overweight” rating and a $9.00 target price for the company. Leerink Partners initiated coverage on shares of MannKind in a research note on Monday, September 9th. They set an “outperform” rating and a $8.00 target price on the stock. Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $7.00 to $10.00 in a research note on Thursday. StockNews.com cut MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 7th. Finally, Oppenheimer increased their price target on shares of MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, MannKind has a consensus rating of “Buy” and a consensus price target of $8.88.

MannKind Trading Up 8.7 %

NASDAQ MNKD opened at $6.85 on Monday. MannKind has a 52 week low of $3.17 and a 52 week high of $7.63. The company has a 50-day moving average price of $6.76 and a two-hundred day moving average price of $6.03. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of 97.86 and a beta of 1.28.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of MNKD. Principal Financial Group Inc. grew its position in MannKind by 401.8% in the 3rd quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company’s stock valued at $1,060,000 after purchasing an additional 134,937 shares during the period. Franklin Resources Inc. increased its position in shares of MannKind by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 160,016 shares of the biopharmaceutical company’s stock valued at $1,047,000 after purchasing an additional 4,603 shares during the last quarter. Geode Capital Management LLC increased its holdings in MannKind by 0.4% during the third quarter. Geode Capital Management LLC now owns 6,338,928 shares of the biopharmaceutical company’s stock worth $39,880,000 after buying an additional 24,031 shares during the last quarter. Barclays PLC raised its holdings in shares of MannKind by 186.0% in the 3rd quarter. Barclays PLC now owns 519,865 shares of the biopharmaceutical company’s stock worth $3,271,000 after purchasing an additional 338,121 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of MannKind in the third quarter valued at $413,000. 49.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at MannKind

In other MannKind news, insider Stuart A. Tross sold 55,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the completion of the sale, the insider now owns 967,191 shares of the company’s stock, valued at $7,099,181.94. This trade represents a 5.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steven B. Binder sold 67,536 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $6.89, for a total value of $465,323.04. Following the sale, the director now owns 1,075,026 shares of the company’s stock, valued at approximately $7,406,929.14. This represents a 5.91 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 190,075 shares of company stock valued at $1,325,587. 3.00% of the stock is currently owned by company insiders.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.